Accelerates transformation of AMAG to a Profitable, Multi-Product Specialty Pharmaceutical Company Adds FDA-Approved Therapy Makena® and Complementary Commercial Platform to AMAG Portfolio Projected Pro Forma Combined 2015 Revenues of $350 million and Estimated Annual Cost Synergies of at least $20 million Transaction Expected to be Immediately Accretive to Adjusted Earnings Per Share Conference Call Today at 8am ET to Discuss Transaction
WALTHAM, Mass., Sept.
Sign-up for AMAG Pharmaceuticals, Inc. to Host Conference Call on October 30, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter and Nine Months Ended September 30, 2014 investment picks
AMAG Closes $340 Million Term Loan AMAG and Lumara Health Reaffirm Commitment to Women's Health and Reducing the Risks of Preterm Birth Lumara Executive Ken Wilson to Lead Maternal Health Division Within AMAG WALTHAM, Mass., Nov.
-AMAG Closes $340 Million Term Loan -AMAG and Lumara Health Reaffirm Commitment to Women's Health and Reducing the Risks of Preterm Birth -Lumara Executive Ken Wilson to Lead Maternal Health Division within AMAG
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.